Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.
Cel badania
Opis z rejestru (w języku angielskim):
The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).
All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.
Leczenie w badaniu
Lek / interwencja
Rola
Postać, podanie
ThecaFlex DRx System
Wyrób medyczny
Kryteria udziału
Kryteria w języku angielskim, tak jak w rejestrze.
Kryteria włączenia kto może wziąć udział (9)
Subject is 3 years or older
Subject is diagnosed with SMA and is a candidate for Spinraza treatment as indicated in country-specific label
Subject resistant to lumbar puncture (LP), where resistance is defined as:
Subject with respiratory issues or other comorbidities who is at an increased risk for complications due to the need for repeat anesthesia and imaging radiation exposure to safely perform LP; or
Subjects for whom the treating physician determines implantation of the ThecaFlex DRx™ System is otherwise in the subject's best interest
Subject has been prescribed nusinersen via chronic intrathecal bolus administration in accordance with the country-specific drug labeling
Subject, per Investigator discretion, is able to undergo a percutaneous or open surgical procedure for index port and catheter implantation where at least 7 cm of the ThecaFlex DRx system catheter will be placed intrathecally
Subject (or subject's legally authorized representative) is willing and able to provide written informed consent; and
Subject and parent/caregiver able and willing to complete all clinical investigation procedures, measurements, and visits.
Kryteria wyłączenia kto nie może wziąć udziału (22)
Subject meets any of the contraindications for use of the ThecaFlex DRx System as outlined in the ThecaFlex DRx System Instructions for Use
Presence or history of (< 6 months prior to the procedure): an implanted microinfusion pump, intrathecal catheter, or other intrathecal drug delivery devices/component, or implanted shunt for drainage of cerebrospinal fluid (CSF), or reservoir in the CSF space (note: any ThecaFlex Port and Catheter System must not be placed in the same location as a previous indwelling port and catheter)
Subject is pregnant or nursing or plans to become pregnant during the course of the clinical investigation, or is a woman of childbearing potential or a man of reproductive age who is unwilling or unable to practice contraception, as described in Section 14.10.
Any condition or event, which in the opinion of the Investigator may adversely affect the safety and effective implantation and use of the ThecaFlex DRx system or confound the clinical investigation, including:
Severe structural impediment that may preclude safe implantation of the catheter and port
Major medical events (as defined per investigator's discretion) within 60 days prior to screening; or
Relevant surgeries (e.g., head and neck, back, etc.) within 60 days prior to screening or planned during the duration of the clinical investigation
Space-occupying lesion with mass effect
Posterior fossa mass
Arnold-Chiari malformation
Coagulation abnormalities and/or thrombocytopenia
Insufficient or inadequate skin or underlying fat to adequately protect the port or enough surface area to allow the skin to close safely
Subject is contraindicated for administration of nusinersen per its approved country-specific labeling
History of intrathecal granuloma formation
History of bacterial meningitis or aseptic meningitis within 6 months of screening
History of tumors or other spinal abnormalities documented by magnetic resonance imaging (MRI) or computed tomography (CT) that would interfere with the catheter implantation procedures or CSF circulation
History of hydrocephalus
Diagnosed degenerative muscular disease other than SMA
History of depression, cognitive impairment, or another psycho-behavioral problem that in the opinion of the Investigator may preclude safe participation in the clinical investigation and
Serious medical condition that, in the opinion of the investigator, may lead to reduced life expectancy beyond 12 months.
Subject is involved in another Investigation Device Exemption Study.
Subject has clinically meaningful immunosuppression, in the opinion of the investigator, either from therapy or a comorbid condition, which, in the opinion of the investigator, makes them a poor surgical candidate due to increased risk of infection.
To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.
Zapytaj o udział w tym badaniu
Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene…
Badane leki:BIIB115+5
Miasta: Katowice, Warszawa, ŁódźWiek: do 17.99 latSponsor: Biogen Idec Research Limited
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy…
Badane leki:BIIB115+12
Miasta: Kraków, WarszawaWiek: do 64 latSponsor: Biogen Idec Research Limited
An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered via the ThecaFlex DRx™ System (PIERRE-PK)
Badane leki:BIIB058
Miasta: Kraków, ŁódźWiek: od 0 latSponsor: Biogen Idec Research Limited
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Badane leki:RO7034067
Miasta: Gdańsk, Uniwersyteckie Centrum Kliniczne, WarszawaWiek: do 17.99 latSponsor: F. Hoffmann-La Roche AG
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function…
Badane leki:RO7034067
Miasta: Gdańsk, WarszawaWiek: do 17.99 latSponsor: F. Hoffmann-La Roche AG
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.